Skip to main content

Table 2 Variables with a significant effect on the four week change in uric acid. Results from multivariable regression analysis

From: Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

  All patients Diabetes No diabetes
  Estimated influence on uric acid concentration (μmol/L): p-value: Estimated influence on uric acid concentration (μmol/L): p-value: Estimated influence on uric acid concentration (μmol/L): p-value:
Change in glucose concentration (for 1 mmol/L decrease) * 1.6 (± 0.3) <0.0001 1.7 (± 0.3) <0.0001 -3.8 (± 1.5) 0.01
Weight loss, for 1% decrease * 2.5 (± 0.3) <0.0001 2.9 (± 0.4) <0.0001 0.6 (± 0.7) 0.4
LDL change (for 1 mmol/L decrease) † -7.4 (± 0.9) <0.0001 -6.4 (± 1.1) <0.0001 -11.7 (± 2.0) <0.0001
Triglyceride change (for 1 mmol/L decrease) -6.3 (± 1.1) <0.0001 -6.0 (± 1.2) <0.0001 -7.4 (± 2.6) 0.004
Change in systolic blood pressure (for 1 mmHg decrease) 0.3 (± 0.07) <0.0001 0.3 (± 0.08) 0.0002 0.1 (± 0.1) 0.5
Use of fibrates -14.7 (± 2.1) <0.0001 -15.3 (± 2.2) <0.0001 -8.9 (± 5.7) 0.1
Triglyceride concentration at baseline (for 1 mmol/L increment) 5.5 (± 0.9) <0.0001 5.8 (± 1.0) <0.0001 3.6 (± 2.2) 0.1
Use of diuretics 11.9 (± 1.2) <0.0001 12.1 (± 1.4) <0.0001 10.0 (± 2.9) 0.0007
Uric acid concentration at baseline (for 1 μmol/L increment) -0.2 (± 0.01) <0.0001 -0.3 (± 0.007) <0.0001 -0.2 (± 0.02) <0.0001
Creatinine clearance at baseline (for 1 mL/min/1.73 m2 increment) -0.08 (± 0.02) <0.0001 -0.07 (± 0.02) <0.0001 -0.2 (± 0.06) <0.0001
Change in creatinine clearance (for 1 mL/min/1.73 m2 increase) 0.1 (± 0.01) <0.0001 0.1 (± 0.02) <0.0001 0.2 (± 0.05) <0.0001
Male gender 10.2 (± 1.4) <0.0001 10.2 (± 1.6) <0.0001 11.1 (± 3.5) 0.001
Waist circumference at baseline (for 1 cm increment) 0.2 (± 0.07) 0.001 0.2 (± 0.08) 0.007 0.2 (± 0.1) 0.1
BMI at screening (for 1 kg/m2 increment) 0.5 (± 0.2) 0.01 0.5 (± 0.2) 0.02 0.5 (± 0.4) 0.3
HDL change (for 1 mmol/L decrease) * 5.7 (± 4.0) 0.2 10.0 (± 4.5) 0.03 -10.8 (± 8.3) 0.2
LDL at screening (for 1 mmol/L decrement) 0.3 (± 0.7) 0.6 0.8 (± 0.8) 0.3 -3.6 (± 1.6) 0.02
Type 2 diabetes mellitus 5.9 (± 1.7) 0.0004 -   - -
  1. The stratum "diabetes" includes the patients in the DM only group and the CVD+DM group. "No diabetes" includes the patients in CVD only group. Only variables at a significance level of ≤ 0.05 in overall group or in any of the two groups are presented in table. Analysis was also adjusted for screening features (age, smoking status, a diagnosis of heart failure, systolic and diastolic blood pressure, pulse, glucose concentration at baseline, and HDL cholesterol at baseline), medication use (insulin, aspirin, ACE-inhibitors, calcium channel blockers, statins) and dynamic variables (changes in diastolic blood pressure and pulse). SE = standard error. (*) and (†) indicate a p-value ≤ 0.01 and p-value ≤ 0.05 respectively for differences in the influence on uric acid between patients with and without diabetes.